# Acalabrutinib Chronic Lymphocytic Leukemia trial

> A new phase 2 trial, NCT07582159, adds acalabrutinib to tafasitamab and venetoclax in CLL/SLL; BioQ shows its BTK potency and 121 registered trials.

Data as of 2026-11-06 · Published 2026-11-06 · Updated 2026-11-06 · https://bioq.bio/blog/en/acalabrutinib-nct07582159-chronic-lymphocytic-leukemia

![BioQ search results for the query acalabrutinib, showing the compound's measured targets and registered clinical trials.](https://bioq.bio/blog/img/acalabrutinib-nct07582159-chronic-lymphocytic-leukemia/en/hero.webp)

NCT07582159 is a phase 2 trial from City of Hope Medical Center that combines tafasitamab, acalabrutinib and venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma. In ChEMBL, acalabrutinib's best-measured named target is BTK at pChEMBL 8.59 (KD, 29 exact measurements). ClinicalTrials.gov lists 121 acalabrutinib studies, 81 of them phase 2. All data are as of 2026-11-06.

## What we asked about the acalabrutinib Chronic Lymphocytic Leukemia trial

The registry entry is titled "Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma". It is a PHASE2 study sponsored by City of Hope Medical Center. The listed conditions are chronic lymphocytic leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma and small lymphocytic lymphoma. The registered start date falls after the data date of this post, so the trial is a registration, not a result.

The trial tests a three-drug combination, so the data on acalabrutinib alone cannot say what the combination will do. We asked what is already on record about acalabrutinib itself:

- Which targets has it been measured against, and how potently?
- How many other trials are registered, and in which phases?
- How is the compound identified across databases?

We ran one query: acalabrutinib.

## What BioQ returned

The query drew on 3 distinct resources (ChEMBL, ClinicalTrials.gov and PubChem) in 3 engine queries, which took 0.27 engine seconds in total.

**Identity.** PubChem lists acalabrutinib as CID 71226662, with InChIKey WDENQIQQYWYTPO-IBGZPJMESA-N and 15 synonyms. It maps to CHEMBL3707348 in ChEMBL, which is the identifier used for the potency data below.

**Potency.** ChEMBL holds measurements against 59 targets for this compound, and 19 of them have exact measurements. The table shows the 8 strongest by best pChEMBL, which is the negative log10 of the molar potency.

| ChEMBL target | Gene | Best pChEMBL | Type | Exact measurements |
|---|---|---|---|---|
| CHEMBL4296503 | — | 10.85 | IC50 | 2 |
| CHEMBL5251 | BTK | 8.59 | KD | 29 |
| CHEMBL4246 | TEC | 8.26 | KD | 8 |
| CHEMBL1824 | ERBB2 | 8.13 | KD | 4 |
| CHEMBL612545 | — | 8.1 | EC50 | 1 |
| CHEMBL4483266 | — | 7.89 | IC50 | 1 |
| CHEMBL3009 | ERBB4 | 7.8 | IC50 | 5 |
| CHEMBL2250 | BLK | 7.75 | KD | 1 |

![BioQ target view for acalabrutinib listing ChEMBL targets ranked by best pChEMBL value with exact measurement counts](https://bioq.bio/blog/img/acalabrutinib-nct07582159-chronic-lymphocytic-leukemia/en/targets.webp)
*BioQ target view for the query acalabrutinib.*

**Other trials.** ClinicalTrials.gov matches 121 studies with acalabrutinib as an intervention. The matches break down as 33 phase 1, 81 phase 2 and 18 phase 3. The table below is a page of 6 of them.

| Trial | Phase | Status | Sponsor | Start | Enrollment |
|---|---|---|---|---|---|
| NCT03932331 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | AstraZeneca | 2020-04 | 105 |
| NCT04722172 | PHASE2 | ACTIVE_NOT_RECRUITING | Memorial Sloan Kettering Cancer Center | 2021-05 | 55 |
| NCT04646395 | PHASE2 | ACTIVE_NOT_RECRUITING | International Extranodal Lymphoma Study  | 2021-10 | 26 |
| NCT05943496 | PHASE1 | RECRUITING | OHSU Knight Cancer Institute | 2023-10 | 27 |
| NCT04257578 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | University of Washington | 2020-12 | 23 |
| NCT04505254 | PHASE2 | ACTIVE_NOT_RECRUITING | M.D. Anderson Cancer Center | 2020-08 | 60 |

## What it means and how to read it

BTK is the clearest line in the potency table. Its best value is 8.59 as a KD, and it has 29 exact measurements, the most of any target in the list. That makes it the best-documented target here, which is consistent with the mechanism usually given for acalabrutinib. The numbers describe binding or activity in assays, not clinical effect.

Read the table with these points in mind:

- The top row, CHEMBL4296503, has a higher best value (10.85, IC50) but only 2 exact measurements and no gene symbol in this view. A strong value from few measurements is a prompt to open the underlying assays, not a ranking of importance.
- TEC (8.26, KD, 8 exact measurements) and ERBB2 (8.13, KD, 4 exact measurements) follow BTK. ERBB4 (7.8, IC50) and BLK (7.75, KD) also appear. These are measured activities beyond BTK, and the data alone do not show whether any of them matters in a patient.
- The best value per target mixes assay types (KD, IC50, EC50), so values of different types are not strictly like for like.

On trial context, the rows shown are a page, not a ranking. They are phase 2, phase 1/2 or phase 1 studies, and most are active but not recruiting. Phase counts apply to all 121 matched studies, and combined-phase studies may be counted under more than one phase, so do not add the three counts together. NCT07582159 adds one more phase 2 entry, with a combination partner list (tafasitamab, venetoclax) that distinguishes it from a plain acalabrutinib study.

The manual route to the same picture means a ChEMBL compound page, a ClinicalTrials.gov search with intervention filters and a PubChem lookup to reconcile names. BioQ ran the 3 queries in 0.27 engine seconds and returned each result with its source named. The time you save is mostly the identifier matching and the reading of three different layouts.

## How to reproduce it in BioQ

1. Open BioQ and enter the single query below.
2. Open the targets view and sort by best pChEMBL. Check the exact-measurement column before trusting a high value.
3. Open the trials view and filter by condition (chronic lymphocytic leukemia) and phase to find NCT07582159 next to related studies.
4. Note the ChEMBL identifier CHEMBL3707348 if you want to go from the summary to the individual assays.

```text
acalabrutinib
```

[Open this query in BioQ](https://bioq.bio/login?next=%2Fapp%23q%3Dacalabrutinib)

## Limits: what the data do not show

- The data say nothing about the outcome of NCT07582159. It is a registration with a future start, with no results.
- The potency data are for acalabrutinib alone. Tafasitamab and venetoclax were not queried here, and interactions in the combination are outside these facts.
- A pChEMBL value is an in-vitro measure. It does not give dosing, response or tolerability information, and nothing here is treatment guidance.
- We did not query cancer-model dependency data for BTK, so this post makes no claim about how essential BTK is in leukemia cell lines.
- Some targets in the table have no gene symbol in this view, and others rest on 1 or 2 exact measurements. Treat them as leads to check.
- The trial list is a page of 6 from 121, selected by the registry's ordering and not by relevance to chronic lymphocytic leukemia.

## Data and method
The numbers on this page were read from the BioQ engine on 2026-11-06 (3 queries, 0.3 s of engine time in total). The tables are generated by code from the engine's answers; the text only restates them.

`/chembl_potency`, `/clinicaltrials`, `/compound`

## Sources
- Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (2026) — [https://clinicaltrials.gov/study/NCT07582159](https://clinicaltrials.gov/study/NCT07582159)

Run the same query yourself: [acalabrutinib](https://bioq.bio/login?next=%2Fapp%23q%3Dacalabrutinib)

*For research use only. This page summarises public data and is not medical advice.*

BioQ is an AI search engine and agent with one goal: making biology research 100X faster. Ask in the web app, over the REST API, or from Claude, ChatGPT or Cursor through MCP.

## Queries used

- [`acalabrutinib`](https://bioq.bio/login?next=%2Fapp%23q%3Dacalabrutinib)

## Frequently asked questions

### What does NCT07582159 test?

It is a PHASE2 trial from City of Hope Medical Center that combines tafasitamab, acalabrutinib and venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma. The registered start date falls after the 2026-11-06 data date, so no results exist yet.

### How potent is acalabrutinib against BTK in ChEMBL?

The best BTK value is pChEMBL 8.59 as a KD, backed by 29 exact measurements. That is the largest measurement count among the 8 strongest targets listed.

### How many acalabrutinib trials are registered on ClinicalTrials.gov?

BioQ matches 121 studies with acalabrutinib as an intervention: 33 phase 1, 81 phase 2 and 18 phase 3. The phase counts cover all matched studies, and combined-phase studies may be counted more than once.

### Does acalabrutinib hit targets other than BTK?

ChEMBL records measurements against 59 targets, and 19 have exact measurements. TEC (8.26, KD), ERBB2 (8.13, KD), ERBB4 (7.8, IC50) and BLK (7.75, KD) appear among the strongest, but these are assay values and not evidence of clinical effect.

## Sources

- Trial: [Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://clinicaltrials.gov/study/NCT07582159) (2026)
- Dataset: [ClinicalTrials.gov](https://clinicaltrials.gov/)
- Dataset: [PubChem](https://pubchem.ncbi.nlm.nih.gov/)

> Results come from public databases as of the date shown and may change. BioQ gives research information, not medical advice.
